#WCLC20

Joshua Bauml, MD

Jbauml

Next up @JSabari is presenting data on amivantamab in EGFR Exon20ins+ NSCLC. I have participated in the development of amivantamab, though I am not on this particular abstract. Excited to

Joshua Bauml, MD

Jbauml

Tonight at #WCLC20 we saw a RCT presented by Dr Lai on behalf of co-authors looking at immunotherapy in patients with EGFR+ NSCLC. Patients had disease that progressed on at

Joshua Bauml, MD

Jbauml

Up next I am going to go through the CodeBreaK100 trial, evaluating AMG510 in patients with KRAS G12C+ NSCLC. I know a lot of people have already gone over these

Stephen V Liu

StephenVLiu

#WCLC20 Passionate plea to clinical investigators designing clinical trials by @jillfeldman4 at the @IASLC plenary. Eloquent articulation at some of the fundamental flaws in our research infrastructure. This is a

Joshua Bauml, MD

Jbauml

The first abstract I want to talk about is a featured poster I am honored to present on behalf of my coauthors. FP14.06. This was a multicenter effort across North

Stephen V Liu

StephenVLiu

#WCLC20 The plenary presentation by @GoldmanLisa on patient-directed research and lessons in partnership is a can't miss and gives important insight into the evolution of clinical research #LCSM @IASLC @OncoAlert

Dr Riyaz Shah

DrRiyazShah

CONFIRM: Fantastic presentation by our very own Prof Fennell. Pleural or peritoneal. Max 12m of therapy. PDL1+ in 29-37% which is a bit lower than I've heard. #WCLC20 #mesothelioma importantly

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.